Arbutus Biopharma (ABUS) Tops Q1 EPS by 10c, Beat on Revenues

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.29), $0.10 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $15.6 million versus the consensus estimate of $3.1 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance